Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pannexin 1 inhibitor (Salipro Biotech)
- Development stage
- Preclinical
- Lead developer
- Salipro Biotech
- Modality
- Small Molecules, Antibody-Based Therapeutics
01
Overview
Salipro Biotech-Pannexin 1-CNS Pain is a preclinical therapeutic program developed by Salipro Biotech in collaboration with an undisclosed partner. The program targets Pannexin 1 (Panx1), a transmembrane protein that forms large-pore channels responsible for the release of adenosine triphosphate (ATP) and other pro-inflammatory mediators. By inhibiting Panx1, the drug aims to mitigate neuroinflammation and pathological signaling associated with chronic and central nervous system (CNS) pain. The development leverages the proprietary Salipro® platform, which stabilizes membrane proteins in their native-like lipid environment to enable the discovery of ligands against challenging targets like ion channels and transporters.
- Other names
- Pannexin 1 programPannexin1 programPannexin-1 programSalipro Pannexin 1
02
Targets
PANX1 (Pannexin-1)
Beyond the preview
Go deeper on Pannexin 1 inhibitor (Salipro Biotech).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pannexin 1 inhibitor (Salipro Biotech).